How understanding evolved
French physician François Boissier de Sauvages de Lacroix coined the term "alopecia areata" in 1763. Nineteenth-century theories blamed nerves or germs, but by the late 20th century the "swarm of bees" of lymphocytes around follicles under the microscope and links with other autoimmune conditions had established it as an autoimmune disease. In 2010 Columbia University geneticist Angela Christiano's genome-wide study pinpointed immune genes, paving the way for JAK inhibitors. In 2022 the FDA approved baricitinib (Olumiant), the first pill for severe alopecia areata, followed by ritlecitinib (Litfulo) in 2023.
Symptoms and triggers
Hair typically falls out suddenly in smooth, round patches that don't itch or hurt. Short "exclamation-mark" hairs, narrower at the base, often line the edges. Patches can merge into total scalp loss (alopecia totalis) or full body hair loss (alopecia universalis), and nails may develop tiny pits. Genetics set the stage; severe stress or illness may pull the trigger. It often occurs alongside eczema, thyroid disease, and vitiligo. It has nothing to do with gradual thinning at the crown and temples, which is male- or female-pattern hair loss.
Treatment and living with it
Small single patches may regrow on their own, but steroid injections into the patch are the usual first-line treatment. More extensive loss may call for contact immunotherapy, oral steroids, or immunosuppressants, and when over half the scalp is affected, JAK inhibitors are now an option. Relapses are common, so think long-term, and don't overlook the anxiety and depression that visible hair loss can bring—support groups like NAAF can help. Special shampoos and home remedies lack evidence.
This article is general health information and is not a substitute for diagnosis or treatment. If symptoms persist, see a doctor.
FAQ
- Is it caused by stress?
- Stress can be a trigger, but the root cause is an immune malfunction.
- Will my hair grow back?
- Usually, within a year—though widespread or childhood-onset cases relapse more often.
Sources reviewed: 2026-10-26
References
- Gilhar, A., Etzioni, A., & Paus, R. (2012). Alopecia areata. NEJM, 366(16), 1515–1525.
- King, B., et al. (2022). Two phase 3 trials of baricitinib for alopecia areata. NEJM, 386(18), 1687–1699.
- Sauvages de la Croix, F. B. (1763). Nosologia methodica.